Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03364153 · ClinicalTrials.gov registry record · Phase 2
Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)
A Phase 2 study, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
NCT03364153 is a Phase 2 study that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 121 participants.
The verdict
NCT03364153, a Phase 2 study, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of avacincaptad pegol intravitreal injection compared to Sham in participants with autosomal recessive Stargardt disease 1 (STGD1).
Interventions
- DRUG Sham
- DRUG avacincaptad pegol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2018-01-12 |
| Est. Completion | 2025-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03364153
The ClinicalTrials.gov registry entry for NCT03364153 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham is the first listed.
NCT03364153 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03364153 about?
NCT03364153 is a clinical study titled "Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)". The purpose of this study is to evaluate the safety and efficacy of avacincaptad pegol intravitreal injection compared to Sham in participants with autosomal recessive Stargardt disease 1 (STGD1).
What is the current status of trial NCT03364153?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2018-01-12. Estimated completion is 2025-03-31.
What interventions are being tested in trial NCT03364153?
The interventions under investigation include: Sham (DRUG), avacincaptad pegol (DRUG).
Who is sponsoring clinical trial NCT03364153?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.